JMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Mirum Pharmaceuticals (MIRM) and raises the price target from $64 to $69.
February 29, 2024 | 7:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities raises Mirum Pharmaceuticals' price target from $64 to $69, maintaining a Market Outperform rating.
The increase in price target by JMP Securities, a reputable financial firm, signals a strong vote of confidence in Mirum Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100